Literature DB >> 15950807

Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the palliative treatment of malignant mesothelioma of the pleura: the Heidelberg experience.

Marc W Münter1, Christian Thieke, Thieke Christian, Anna Nikoghosyan, Nikoghosyan Anna, Simeon Nill, Nill Simeon, Jürgen Debus, Debus Jürgen.   

Abstract

Intensity modulated radiation therapy (IMRT) is a new promising treatment technique, which allows a more conformal application of the dose to the tumor volume, as compared to conventional radio-oncological approaches, while protecting the surrounding normal tissue more accurately. This manuscript presents the final results of IMRT in the treatment of unresectable pleural mesothelioma in Heidelberg.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950807     DOI: 10.1016/j.lungcan.2005.03.031

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  4 in total

1.  Novel radiation therapy approaches in malignant pleural mesothelioma.

Authors:  Andreas Rimner; Kenneth E Rosenzweig
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.

Authors:  Kenneth E Rosenzweig; Marjorie G Zauderer; Benjamin Laser; Lee M Krug; Ellen Yorke; Camelia S Sima; Andreas Rimner; Raja Flores; Valerie Rusch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-18       Impact factor: 7.038

3.  Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.

Authors:  Stephanie E Combs; Steffen Heeger; Renate Haselmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  BMC Cancer       Date:  2006-05-18       Impact factor: 4.430

4.  Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.

Authors:  Christina Schröder; Isabelle Opitz; Matthias Guckenberger; Rolf Stahel; Walter Weder; Robert Förster; Nicolaus Andratschke; Olivia Lauk
Journal:  Front Oncol       Date:  2019-09-26       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.